Literature DB >> 15661391

Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.

Upma Gulati1, Kshama Kumari, Wenxin Wu, Wendy A Keitel, Gillian M Air.   

Abstract

There is still uncertainty on the correlates of protection by influenza vaccine. To determine the relationship between hemagglutination-inhibition (HI) titer and the specificity and avidity of serum antibodies, we analyzed serum from a longitudinal trial (1983-1987) of influenza vaccine efficacy [Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997;15(10):1114-22 ]. We captured native virus particles with fetuin and separately measured relative antibody levels and avidities of antibodies against native glycoproteins and antibodies against denatured viral proteins. Most subjects had pre-existing antibodies against A/Victoria/75 and, although 70% had >two-fold increased antibodies against A/Philippines/82 after vaccination, only 30% showed increased antibodies to A/Victoria/75 indicating no dominance of original antigenic sin. There was variation in the levels of antibodies to unfolded antigens compared to native, but antibodies against denatured proteins never exceeded those against native virus. In some cases, the avidity increased without a significant increase in antibody concentration, which might explain why some vaccinees with low HI titer demonstrate adequate protection. We found that the negative correlation between pre-vaccination HI titer and the increase after vaccination is also seen when antibodies are measured directly, but that there is little relationship between HI titer and antibodies against native glycoproteins, either in amount or avidity. Our assay, which has also been adapted for recent influenza viruses that do not bind to fetuin, may be useful for vaccine evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661391     DOI: 10.1016/j.vaccine.2004.08.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.

Authors:  Gillian M Air; Jingqi Feng; Tao Chen; Michelle L Joachims; Judith A James; Linda F Thompson
Journal:  J Clin Immunol       Date:  2011-07-06       Impact factor: 8.317

3.  Characterization of pandemic influenza immune memory signature after vaccination or infection.

Authors:  Olivia Bonduelle; Fabrice Carrat; Charles-Edouard Luyt; Catherine Leport; Anne Mosnier; Nora Benhabiles; Anne Krivine; Flore Rozenberg; Nora Yahia; Assia Samri; Dominique Rousset; Sylvie van der Werf; Brigitte Autran; Behazine Combadiere
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

4.  High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.

Authors:  Sarah F Andrews; Kaval Kaur; Noel T Pauli; Min Huang; Yunping Huang; Patrick C Wilson
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

5.  Responders and non-responders to influenza vaccination: A DNA methylation approach on blood cells.

Authors:  Noémie Gensous; Claudio Franceschi; Bonnie B Blomberg; Chiara Pirazzini; Francesco Ravaioli; Davide Gentilini; Anna Maria Di Blasio; Paolo Garagnani; Daniela Frasca; Maria Giulia Bacalini
Journal:  Exp Gerontol       Date:  2018-01-31       Impact factor: 4.032

Review 6.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 7.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

8.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

9.  Reproducibility of serologic assays for influenza virus A (H5N1).

Authors:  Iain Stephenson; Alan Heath; Diane Major; Robert W Newman; Katja Hoschler; Wang Junzi; Jacqueline M Katz; Jerry P Weir; Maria C Zambon; John M Wood
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

10.  Antibody quantity versus quality after influenza vaccination.

Authors:  JingQi Feng; Upma Gulati; Xiaoju Zhang; Wendy A Keitel; David M Thompson; Judith A James; Linda F Thompson; Gillian M Air
Journal:  Vaccine       Date:  2009-10-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.